Latest Regulatory News

Tamboran Resources Corporation reported a 26% reduction in half-year losses as it progresses key natural gas projects in Australia’s Beetaloo Basin and prepares for a major acquisition of Falcon Oil & Gas Ltd.

Origin Energy reports a 45% drop in half-year profit amid lower gas earnings and ongoing investments, while extending Eraring Power Station operations to 2029 to support NSW energy security.

Tamboran Resources has appointed Todd Abbott as CEO and made significant progress in drilling and infrastructure development in the Beetaloo Basin, aiming for first gas sales in the third quarter of 2026.

Oneview Healthcare reported a robust 21% increase in revenue for FY2025, driven by recurring revenue growth and new customer acquisitions. The company is advancing AI-powered solutions and targeting operational breakeven in 2026.

Patrys Limited has appointed Dr Samantha South as its new CEO, aiming to leverage her biotech expertise to fast-track clinical development and commercialisation of its therapeutic antibody pipeline.

Vita Resources NL has secured regulatory approval to launch its first-ever exploration drilling campaign at the promising Ninnis Gold Project in Western Australia’s Northern Goldfields.

Insurance Australia Group Limited has announced a quarterly dividend of AUD 1.6241 per security for its Capital Notes, payable mid-March 2026, reflecting a steady 6.5141% annualised distribution rate.

IAG’s 1H26 results reveal a 35% drop in net profit after tax due to severe weather costs from its RACQI acquisition, yet underlying insurance profit rose 7.6%, supported by solid premium growth and a $200 million share buyback.

Insurance Australia Group’s half year net profit fell 35% to $505 million, weighed down by natural peril claims and integration costs from its RACQI acquisition. Despite this, the insurer maintains its full-year guidance and announces a $200 million share buy-back.

ANZ Group Holdings Limited reported a robust first quarter with a 75% jump in cash profit, driven by cost cuts and revenue growth, signalling early success in its ANZ 2030 strategy.

Critical Resources Limited has successfully completed the first tranche of its capital raising, securing $1.605 million through a substantial share and option issuance. The company now awaits shareholder approval for the second tranche, which involves director participation.

Neuren Pharmaceuticals has initiated a discretionary on-market share buy-back program of up to 5%, citing a strong cash position and undervaluation relative to internal and analyst assessments.